Photo of Bilal Hassan

Bilal Hassan

Bilal’s practice focuses on U.S. customs and import compliance matters, complemented by broad experience in export controls. He regularly advises clients on complex regulatory issues before key U.S. administrative agencies, including U.S. Customs and Border Protection (CPB), the Department of Commerce (DOC), the Department of Homeland Security (DHS), and the Bureau of Industry and Security (BIS).

On April 2, 2026, the Trump Administration issued a proclamation imposing Section 232 tariffs on imports of patented pharmaceutical products and active pharmaceutical ingredients (“APIs”) pursuant to Section 232 of the Trade Expansion Act of 1962 (“Section 232”).